281 related articles for article (PubMed ID: 25738481)
1. Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity.
Chowdhury EK; Ademi Z; Moss JR; Wing LMH; Reid CM;
Medicine (Baltimore); 2015 Mar; 94(9):e590. PubMed ID: 25738481
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study.
Chowdhury EK; Owen A; Ademi Z; Krum H; Johnston CI; Wing LM; Nelson MR; Reid CM;
Am J Hypertens; 2014 Feb; 27(2):199-206. PubMed ID: 24249722
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review.
Park C; Wang G; Durthaler JM; Fang J
Am J Prev Med; 2017 Dec; 53(6S2):S131-S142. PubMed ID: 29153114
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
[TBL] [Abstract][Full Text] [Related]
6. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
UK Prospective Diabetes Study Group
BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
[TBL] [Abstract][Full Text] [Related]
8. Treating essential hypertension. The first choice is usually a thiazide diuretic.
Prescrire Int; 2014 Sep; 23(152):215-20. PubMed ID: 25325125
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
[TBL] [Abstract][Full Text] [Related]
10. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival following the development of heart failure in an elderly hypertensive population.
Sahle BW; Owen AJ; Wing LMH; Beilin LJ; Krum H; Reid CM;
Cardiovasc Ther; 2017 Dec; 35(6):. PubMed ID: 28859261
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?
Siegel KR; Ali MK; Zhou X; Ng BP; Jawanda S; Proia K; Zhang X; Gregg EW; Albright AL; Zhang P
Diabetes Care; 2020 Jul; 43(7):1557-1592. PubMed ID: 33534729
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
[TBL] [Abstract][Full Text] [Related]
19. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.
Nordmann AJ; Krahn M; Logan AG; Naglie G; Detsky AS
Pharmacoeconomics; 2003; 21(8):573-85. PubMed ID: 12751915
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
